25 results about "Alveolus pulmonis" patented technology

The invention provides a compound probiotic for relieving acute lung injury and application of the compound probiotic, and particularly discloses application of the compound probiotic consisting of bifidobacterium animalis YRK-12 and lactobacillus rhamnosus LRa-Y8 in preparation of a medicine for relieving the acute lung injury. Wherein the preservation number of the bifidobacterium animalis YRK-12 is CGMCC (China General Microbiological Culture Collection Center) No.28597; the preservation number of the lactobacillus rhamnosus LRa-Y8 is CGMCC (China General Microbiological Culture Collection Center) No. 34186. Experimental verification shows that the compound probiotics can remarkably relieve acute lung injury induced by lipopolysaccharide (LPS) through a synergistic effect; specifically, the weight loss rate of mice is reduced, pathological injuries of lung tissues are improved (the structural integrity of alveolar alveoli is maintained, and inflammatory cell infiltration is reduced), the levels of proinflammatory factors (IL-1beta, TNF-alpha and IL-6) in serum and lung tissues are reduced, and the level of anti-inflammatory factors (IL-4) is increased, so that the immune balance of the lung is regulated through an intestine-lung axis; and a safe and effective novel micro-ecological regulation strategy is provided for prevention and treatment of acute lung injury.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and a preparation method thereof. The inhalation type pharmaceutical composition comprises an active component and a nano-liposome, and mannose is modified on the surface of the nano-liposome; the active ingredients comprise bulbus fritillariae cirrhosae total alkaloids and platycodin D; the nano-liposome is prepared from the following raw materials: phospholipid, cholesterol and cholesterol-polyethylene glycol 1000-mannose ester. The liposome can be specifically recognized by a mannose receptor highly expressed on the surface of alveolar macrophage through a surface-modified mannose ligand, so that the receptor-mediated endocytosis is started, and the wrapped bulbus fritillariae cirrhosae total alkaloids and platycodin D are efficiently introduced into cells. The inhaled pharmaceutical composition of the present invention collectively pushes macrophages from a pro-inflammatory M1 phenotype to a repairable M2 phenotype. Therefore, the overall curative effect of the combination of the two components is far better than that of the independent use of any component.

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for treating pneumonia, which is characterized in that the traditional Chinese medicine composition is prepared from gypsum, rehmannia, ophiopogon root, rhizoma anemarrhenae and achyranthes bidentata. The composition disclosed by the invention can be used for remarkably reducing the content of inflammatory factors of IL-6, IL-1beta and TNF-alpha in alveolar lavage fluid of a model rat with pneumonia caused by lipopolysaccharide, reducing the number of white blood cells and neutrophils of rat blood and increasing the percentage of lymphocytes and platelets, so that the traditional Chinese medicine composition has a relatively good treatment effect on pneumonia.

Provided is a pharmaceutical for lung regeneration, the pharmaceutical containing vascular endothelial stem cells. Also provided is a method for producing an alveolar organoid, the method comprising a step for three-dimensional co-culture of vascular endothelial stem cells and alveolar epithelial cells. This pharmaceutical for lung regeneration is useful in the treatment of lung disease accompanied by alveolar damage, such as chronic obstructive lung diseases, infectious lung diseases, and pulmonary fibrosis.

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.

The invention discloses an exosome composition containing resveratrol, astragalus membranaceus and ginseng as well as a preparation method and application of the exosome composition, and belongs to the technical field of biological medicines. The exosome composition disclosed by the invention is obtained by inducing alveolar epithelial cells by active ingredients containing resveratrol, an astragalus extract and a ginseng extract and then secreting the alveolar epithelial cells. The preparation method of the exosome composition mainly comprises the following steps: co-culturing the active component and alveolar epithelial cells, and then sequentially carrying out differential centrifugation and ultracentrifugation on the collected cell supernatant to purify the exosome. The invention also provides a pharmaceutical preparation containing the exosome composition. According to the composition, traditional Chinese medicine active ingredients are combined with a modern cell exosome technology, a potential strategy is provided for prevention and treatment of pulmonary fibrosis, and the composition has a good application prospect.

This invention discloses a biomimetic nanoliposome, its preparation method, and its application, belonging to the field of pharmaceutical technology. The invention provides a biomimetic nanoliposome comprising a biomimetic carrier of pulmonary surfactant and astragaloside A and chlorogenic acid encapsulated therein. The biomimetic carrier of pulmonary surfactant comprises: dipalmitoylphosphatidylcholine, dipalmitoylphosphatidylglycerol, cholesterol, dipalmitoylphosphatidylethanolamine-polyethylene glycol, and KL4 polypeptide. Astragaloside A and chlorogenic acid, two active monomers from traditional Chinese medicine, can synergistically exert anti-fibrotic effects through multiple signaling pathways, including downregulating the expression of pro-inflammatory / pro-fibrotic factors, inhibiting alveolar type II epithelial cell senescence, and inhibiting fibroblast activation. The lipid and KL4 components mimic pulmonary surfactant components, facilitating the breakthrough of key physiological barriers in the lungs. After modification with the KL4 polypeptide, active targeted recognition of therapeutic drugs can be achieved.

The present application provides a kind of complex based on aspergillus oryzae spore, it is constituted by carbonized aspergillus oryzae spore microsphere surface and the quercetin loaded in aperture;The average porosity of the carbonized aspergillus oryzae spore microsphere is 25%~45%;The mass of the quercetin accounts for 30%‑50% of the total mass of the complex.The complex of the present application significantly improves the solubility and bioavailability of quercetin, and the optimized aerodynamic diameter ensures efficient alveolar deposition, and the rough surface ensures the rapid uptake of macrophages.In vivo and in vitro ALI model verifies the safety of the complex QU-cASP prepared by the present application and has excellent effect in targeted delivery, inhibition of oxidative stress and regulation of macrophage polarization.The present application also provides a method for preparing the complex, the application of the complex in preparing a drug for relieving acute lung injury, and an inhalable preparation with the complex as the active ingredient.

This invention provides a method for establishing a rat model of COPD to study the medicinal uses and pharmacological effects of Liuwei Buqi Decoction in the treatment of COPD. The traditional Chinese medicines in Liuwei Buqi Decoction are ginseng, astragalus, alpinia oxyphylla, polygonatum odoratum, tangerine peel, and cinnamon. This application provides a basis for the syndrome differentiation and treatment strategy of Liuwei Buqi Decoction by exploring the molecular mechanisms by which Liuwei Buqi Decoction regulates the COPD inflammatory immune network and the molecular mechanisms by which it regulates the lung-gut microecological axis and the inflammatory immune network. Taking the high-incidence syndromes of major diseases during the TCM-advantage stage as a starting point, and based on clinical needs, this study, building upon previous clinical research, uses various techniques such as scRNA-seq, CBA, and metagenomics to explore the molecular mechanism by which Liuwei Buqi Decoction improves airway immune inflammation by regulating the lung microecology in rats with COPD lung-kidney qi deficiency syndrome from the perspective of regulating the lung immune microenvironment and alveolar macrophage polarization. Its mechanism of action was further studied and verified through in vitro experiments.

The invention relates to the field of biological medicine, in particular to a nano-carrier system targeting aging alveolar epithelial cells as well as preparation and application of the nano-carrier system. The preparation method comprises the following steps: carrying out self-assembly on chemically synthesized PEI-Se-Se-BAI1 and si-cGAS to form BAI1-cGAS particles; the alveolar epithelial cells with high expression of Anti-DPP4-Scfv are obtained through gene editing, and the extracellular vesicles alpha-DPP4-MNs are obtained through centrifugation; finally, the BAI1-cGAS and the alpha-DPP4-MNs are subjected to membrane extrusion, and the nano carrier system BAI1-cGAS (at) DNs is prepared. The nano-carrier system can specifically target aged alveolar epithelial cells in pulmonary fibrosis through Anti-DPP4-Scfv, BAI1 is released, mitochondrial outer membrane permeability is inhibited, and mtDNA is prevented from being released to cytoplasm; meanwhile, si-cGAS is released, and activation of a cGAS / STING pathway and a downstream inflammation pathway is inhibited, so that inflammatory aging of alveolar epithelial cells is resisted, and pulmonary fibrosis is treated. The nano-carrier system integrates the advantages of aging cell membrane positioning, responsive drug release, dual inflammation pathway inhibition and the like, specifically delays the aging of alveolar epithelial cells, and provides an efficient, safe and accessible method for treating pulmonary fibrosis.

The invention belongs to the technical field of medicine. The invention discloses an application of forsythiaside A in preparation of a medicine for treating bacterial infectious pneumonia. The method comprises the following steps: firstly, establishing a model of mice bacterial infectious pneumonia caused by tracheal intubation instillation of Pseudomonas aeruginosa in vivo, and applying forsythiaside A to treat, so that the infection symptom of the model mice can be obviously relieved, and the lung inflammatory response can be effectively relieved. The method comprises the following steps: firstly, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, and then, establishing a model of pulmonary alveolar macrophages infected with Pseudomonas aeruginosa, Klebsiella pneumoniae or Acinetobacter baumannii in vitro, so that after forsythiaside A is added, the damage of the macrophages can be effectively alleviated, and the number of infectious bacteria in cytoplasm can be reduced. Experimental results show that forsythiaside A can be effectively used for treating bacterial infectious pneumonia.

The invention discloses application of silybin A in preparation of a medicine for treating idiopathic pulmonary fibrosis, and the technical scheme provided by the invention shows that silybin A inhibits a TGF-beta1 signal transduction pathway by degrading TGF-betaRII, can reduce the collagen content of the lung of an IPF mouse, improve the alveolar structure of the mouse and reduce the levels of HYP, TGF-beta1 and TNF-alpha, and can be used for preparing a medicine for treating idiopathic pulmonary fibrosis. Finally, the anti-fibrosis treatment effect on the IPF mouse is achieved.

The present invention belongs to the field of traditional Chinese medicine technology, and in particular relates to a traditional Chinese medicine composition for treating diffuse interstitial lung disease and its application. The traditional Chinese medicine composition of the present invention is made of the following raw materials in parts by weight: 10-12 parts of Curculigo, 10-20 parts of Epimedium, 30-45 parts of Astragalus, 20-30 parts of Ophiopogon, 15-30 parts of Clemati, 10-15 parts of Kadura Caulis, 10-15 parts of Trachelospermum officinale, 10-15 parts of Earthworm, 10-12 parts of Curcuma, 12-15 parts of Polygonum cuspidatum, 15-20 parts of Fritillaria thunbergii, and 6 parts of Licorice, which has better clinical treatment effect for diffuse interstitial lung disease. Further studies have shown that the above drugs have a synergistic effect after compatibility, and can inhibit alveolar epithelial cell-mesenchymal cell transformation and reduce excessive deposition of extracellular matrix by regulating the abnormal activation of TGF-β1 / Snail and Wnt3a / β-catenin signaling pathways, thereby treating IPF.

The application discloses application of CD244 in a gene editing target point against African swine fever. The application provides application of a substance capable of inhibiting CD244 expression in preparation of a product for treating and / or preventing African swine fever virus infection. Inhibition of expression of the CD244 gene in porcine primary alveolar macrophage (PAM) can significantly interfere with ASFV replication, and overexpression of CD244 can significantly promote ASFV replication in an iPAM cell line. The application provides new materials for research and development of anti-ASFV infection drugs and pig disease-resistant breeding.

The application discloses a kind of Sargassum fusiforme low molecular weight fucoidan, and its preparation method is as follows: S1, defatting treatment;S2, preparation of crude polysaccharide;S3, degradation of crude polysaccharide: Sargassum fusiforme fucoidan crude product is dissolved into polysaccharide solution with water, H2O2 is added, and degradation is carried out under ultraviolet light, to obtain Sargassum fusiforme low molecular weight fucoidan DSFF;S4, purification: Sargassum fusiforme low molecular weight fucoidan DSFF is dissolved into polysaccharide solution with water, loaded on DEAE-52 cellulose anion exchange column and eluted with NaCl solution, the eluate is concentrated and dialyzed, and freeze-drying is obtained.The application of the Sargassum fusiforme low molecular weight fucoidan in the preparation of drugs with anti-PM2.5 lung injury effect.The Sargassum fusiforme low molecular weight fucoidan of the application has low molecular weight, is easy to absorb, and has high bioavailability.The research of the application lays a foundation for the development of Sargassum fusiforme fucoidan related lung alveolus protection products.

The present application relates to the technical field of nucleic acid detection, and discloses a general primer pair for detecting the genus of Segniliparus and application thereof. The detection primer pair and identification method provided by the present application are applicable to all species of the genus of Segniliparus, including but not limited to Segniliparus rugosus, and especially unnamed ANI species. The amplification method provided by the present application has low requirements for templates, and is applicable to clinical original samples such as sputum, alveolar lavage fluid, pleural and peritoneal fluid, culture, and environmental original samples such as water, soil and air, and extracted nucleic acid, and does not depend on culture. The method is fast and low-cost, and has low requirements for equipment and detection personnel, and is applicable to laboratories at all levels. The detection reagent based on the present application can be widely applied to related fields such as environmental monitoring, clinical precise detection and epidemiological research.

The invention discloses a pharmaceutical composition containing a pseudo-ginseng extract as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The invention provides a pharmaceutical composition containing a pseudo-ginseng extract, and tests prove that the pharmaceutical composition containing the pseudo-ginseng extract has a treatment effect on bacterial pneumonia induced by klebsiella pneumonia. Specifically, the pharmaceutical composition containing the pseudo-ginseng extract can significantly reduce the levels of IL-6, IL-1beta and TNF-alpha in alveolar lavage fluid; the mouse lung index is obviously reduced; the bacterial load in the lung tissue of the mouse is obviously reduced; the mouse lung tissue injury degree is obviously reduced; the number of neutrophils and the number of leukocytes in mouse blood are obviously reduced; the composition also has the effect of remarkably relieving increase of inflammatory factors in serum caused by klebsiella pneumoniae, and the effect is equivalent to or superior to that of a positive control drug ceftriaxone sodium. The invention provides a new choice and idea for clinical treatment of bacterial pneumonia.

The invention relates to the technical field of biology, and particularly discloses a method for inducing differentiation and maturation of alveolar organs and application of the method. The method for inducing differentiation and maturation of the alveolar organoid comprises the following steps: performing differentiation induction on the alveolar organoid in an early alveolar stage in a suspension culture manner; the suspension culture is carried out in an alveolar organ culture medium, and polydopamine nanoparticles are additionally added into the alveolar organ culture medium. In ALO in-vitro long-term culture, through combination of suspension culture and PDA NPs, AT2 differentiation efficiency in ALO is improved, AT2 function maturation is promoted, and the application effect of ALO in the fields of lung injury repair and transplantation regeneration can be improved.

The invention relates to the technical field of nucleic acid detection, and discloses a universal primer pair for detecting stenotrophomonas and application of the universal primer pair. The detection primer pair and the identification method provided by the invention are generally used for all strains of stenotrophomonas, including but not limited to stenotrophomonas maltophilia, especially unnamed ANI strains. The amplification method provided by the invention has low requirements on a template, is suitable for clinical original samples such as sputum, alveolar lavage fluid, hydrothorax and ascites, culture and the like, environment original samples such as water samples, soil, air and the like and extracted nucleic acid, and does not depend on culture. The method is rapid and low in cost, has low requirements on equipment and detection personnel, and is applicable to all levels of laboratories. The detection reagent based on the invention can be widely applied to the related fields of environmental monitoring, clinical precise detection, epidemiological research and the like.

This invention belongs to the field of new pharmaceutical technology and relates to a nebulized inhalation formulation for treating chronic obstructive pulmonary disease (COPD) and asthma, and its preparation method. Specifically, it relates to a nebulized inhalation solution formulation of an aminotetraphenylporphyrin photosensitizer (D4) with high light sensitivity. This invention uses an aminotetraphenylporphyrin photosensitizer (D4) as the active ingredient for treating COPD and asthma. The prepared D4 nebulized inhalation formulation comprises the following components: 200-400 μg / ml of the small molecule compound D4 solution, 0.1%-0.6% w / w acrylic polymer carbopol / 3%-25% w / w poloxamer 407 / 3%-25% w / w poloxamer 188, appropriate amounts of isotonic agent, pH adjuster, and purified water. The D4 nebulized inhalation formulation prepared by this invention, after excitation with a 650nm laser, shows significant therapeutic effects on COPD and asthma. After treatment, the alveolar septa narrowed, inflammatory infiltration decreased, airway changes were alleviated, and the thickness of the airway wall, smooth muscle layer, and basement membrane layer decreased. This method is highly effective, low in toxicity, highly targeted, has high nebulization efficiency, a short treatment cycle, and the preparation method is simple, convenient, and reliable, facilitating the establishment of quality control standards in production and promoting drug quality monitoring and large-scale production.

The invention provides preparation and application of engineered extracellular vesicles modified by SP-D protein, and belongs to the technical field of biological medicine. The invention provides engineered extracellular vesicles (SP-D-EVs) modified by utilizing pulmonary surfactant protein D (SP-D), the SP-D-EVs have the effect of actively targeting alveolar epithelium, are high in targeting property and are efficiently enriched in the lung, and a new delivery platform is provided for accurate treatment of lung diseases. The SP-D-EVs disclosed by the invention is good in expression in form, protein and surface modification detection, has good membrane integration stability, can be used for remarkably improving and treating acute lung injury, and shows anti-inflammatory and tissue repair effects. The SP-D-EVs disclosed by the invention can also be used as a universal platform and a delivery carrier, is suitable for drug delivery research of various lung diseases, and has relatively high universality and conversion value.

The application belongs to the technical field of new application of medicines, and particularly relates to hydroxycinnamic acid derivatives, a preparation method and application thereof. The ARDS model is induced by LPS tracheal instillation combined with hydroxycinnamic acid derivatives, the alveolar lavage fluid cell count is determined, and the pathological characteristics and the expression level of inflammatory genes of lung tissues are detected; the results show that the hydroxycinnamic acid derivatives can significantly reduce lung cell infiltration, alleviate lung tissue damage and reduce the expression level of inflammatory factors.

The invention belongs to the technical field of biomedicine, and aims to solve the problems that virus gene mutation can generate new biological characteristics, so that the efficacy of an existing vaccine is reduced, and the condition of an infected pig is aggravated, a porcine reproductive and respiratory syndrome virus strain is obtained by utilizing Marc-145 and iPAM cell separation and identification, and the strain can be stably proliferated in the Marc-145 cell, so that the porcine reproductive and respiratory syndrome virus strain can be used for preparing a porcine reproductive and respiratory syndrome virus strain. The strain can be infected in immortalized swine alveolar macrophages, and has application potential as a vaccine candidate strain.

The application belongs to the technical field of medicine, and particularly relates to a Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus composition for regulating macrophage polarization and application thereof. The Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus composition is obtained by mixing Nauclea diderrici Kotschy and Alpiniae oxyphyllae Fructus, adding water, heating extraction, reducing pressure concentration and drying. The composition obtained by the application can significantly reduce pro-inflammatory factors and improve anti-inflammatory factors through bidirectional regulation of alveolar macrophage polarization, and promote lung tissue repair, thereby providing a new scheme for clinical treatment of acute lung injury.